Media Thread, page-17925

  1. 1,636 Posts.
    lightbulb Created with Sketch. 13929

    Cema-cel also has breakthrough therapy designation for 3rd line r/r LBCL. This was all public information prior to the licensing of Azer-cel. 3rd line treatment is obviously not a large market, so they have attacked front-line consolidation. Very smart commercialization strategy utilizing the advantages of allogeneic.

    You are also correct re patient recruitment numbers and timelines, Bav. Nice work.

    https://crisprmedicinenews.com/news/allogene-therapeutics-activates-first-clinical-sites-for-pivotal-phase-2-trial-of-cema-cel/#:~:text=In%20June%202022%2C%20the%20FDA,LBCL%20launched%20in%20June%202024.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.1¢
Change
0.000(0.00%)
Mkt cap ! $82.13M
Open High Low Value Volume
1.1¢ 1.2¢ 1.1¢ $232.6K 21.12M

Buyers (Bids)

No. Vol. Price($)
14 9092611 1.1¢
 

Sellers (Offers)

Price($) Vol. No.
1.2¢ 11109407 47
View Market Depth
Last trade - 12.30pm 26/06/2025 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.